Opinion|Videos|June 21, 2024

AUA 2024: Outlining BOND-003 Data for NMIBC Therapy

Author(s)Gary Steinberg, MD, FACS

Expert urologist reviews the BOND-003 study, discussing its design, interim outcomes, safety and efficacy data, and the potential for cretostimogene grenadenorepvec to provide a durable response in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Episodes in this series

Video 1 "Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC"

EP. 1 Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC

Video 2 - "Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC"

EP. 2 Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC

Gary D. Steinberg, MD, an expert on bladder cancer

EP. 3 Intravesical Novel Therapy for HR BCG-Unresponsive NMIBC

Gary D. Steinberg, MD, an expert on bladder cancer

EP. 4 AUA 2024: Outlining BOND-003 Data for NMIBC Therapy

Gary D. Steinberg, MD, an expert on bladder cancer

EP. 5 BOND-003: Clinical Implications for HR BCG-Unresponsive NMIBC Treatment

Gary D. Steinberg, MD, an expert on bladder cancer

EP. 6 AUA 2024: Key Takeaways & Future of NMIBC Management

Video content above is prompted by the following question(s):

Focusing on the BOND-003 study, please review the study design, key interim outcomes, and safety and efficacy data.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Alternative BCG strains may help address ongoing supply challenges in NMIBC

ByEugene B. Cone, MD

September 11th 2026

Phase 3 trial of padeliporfin VTP completes treatment in LG-UTUC

ByHannah Clarke

September 10th 2026

John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC

ByJohn P. Sfakianos, MD

September 9th 2026

Dabogratinib shows early activity in FGFR3-altered LG-IR-NMIBC

ByHannah Clarke

September 9th 2026

The critical role of advocacy in urologic oncology

ByRuchika Talwar, MD,Lan Anh Galloway, MD

September 9th 2026

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

AI-generated profiles impersonate female urologists to market ED products online

Alternative BCG strains may help address ongoing supply challenges in NMIBC

Doublet or triplet? Urologists weighs in on mCSPC options

Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA

Prior auth, step therapy, and consolidation pressure: Independent urology's challenge